This episode is hosted by Day Zero advisory council member Suchi Saria, Ph.D., Founder and CEO, Bayesian Health. Dr. Saria spoke with Dr. Michael D. Abramoff about the founding of his Autonomous AI diagnostics company, Digital Diagnostics – and about how Autonomous AI may play a more significant role in healthcare in the near future.

For More Info about Day Zero Visit:
[ Ссылка ]

Dr. Michael D. Abramoff, MD, PhD is a neuroscientist, fellowship-trained retina specialist, computer engineer and entrepreneur. He is Founder and Executive Chairman of Digital Diagnostics, Inc., the first company ever to receive FDA clearance for an autonomous AI diagnostic system, in any field of medicine. In primary care, it can instantaneously diagnose diabetic retinopathy and diabetic macular edema at the point of care without human oversight, in order to improve access and quality of care, remove health inequities, and lower cost. He is the Robert C. Watzke, MD Professor of Ophthalmology and Visual Sciences at the University of Iowa, with joint appointments in the College of Engineering. With his collaborators, he developed an ethical foundation for healthcare AI based on "metrics for ethics", that continues to used for the design, training, validation, and regulatory and payment pathways for autonomous AI, addressing such issues as AI bias, AI liability, patient and population outcomes, and data usage. As the author of over 300 peer-reviewed publications, his scientific work has been cited 40,000 times, and he is the inventor on 18 issued patents as well as many patent applications. Dr. Abramoff has mentored dozens of engineering graduate students, ophthalmology residents, and vitreoretinal surgery fellows.

свернуть